ARQ 092

ARQ 092 is an allosteric, orally bioavailable, pan-Akt inhibitor (IC50s = 5.0, 4.5, and 16 nM for Akt1, Akt2, and Akt3, respectively).1 It is selective for Akt isoforms over a panel of 303 other kinases.1 ARQ 092 binds inactive Akt and prevents membrane localization and full Akt activation.1,2 It also directly inhibits the membrane-associated active form of Akt, preventing phosphorylation of downstream targets.1,2 ARQ 092 inhibits the proliferation of a wide range of cancer cells in vitro, inhibits the mutated Akt form found in Proteus syndrome, and attenuates heterotypic cell-cell interactions in a mouse model of sickle cell disease.1,2,3,4WARNING This product is not for human or veterinary use.

An orally bioavailable pan-Akt inhibitor

432.5

≥98%

Biochemicals/Kinase Inhibitors/PKB/Akt/Small Molecule Inhibitors/Kinases

Formal_Name:3-[3-[4-(1-aminocyclobutyl)phenyl]-5-phenyl-3H-imidazo[4,5-b]pyridin-2-yl]-2-pyridinamine

NC1=NC=CC=C1C2=NC(C=C3)=C(N2C4=CC=C(C5(N)CCC5)C=C4)N=C3C6=CC=CC=C6

C27H24N6

1313881-70-7

≥ 4 years

DMF: 12.5 mg/ml DMF:PBS (pH 7.2) (1:2): 0.33 mg/ml DMSO: 10 mg/ml Ethanol: 0.3 mg/ml